Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

(0.0% 1d) (0.0% 1m) (8.9% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

Press-releases

LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Published: 2023-11-15 (Crawled : 15:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 36.48% | O: -7.3% H: 6.48% C: 4.17%
therapeutics agreement

Graphite Bio Announces Departure of Chief Financial Officer
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 15.22% | O: -1.81% H: 5.54% C: -1.85%
financial

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
Published: 2023-03-20 (Crawled : 00:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 29.27% | O: -0.41% H: 0.41% C: -0.82%
business year financial results

Adaptimmune Announces Changes to Board of Directors
Published: 2023-02-16 (Crawled : 15:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 42.6% | O: -0.9% H: 5.43% C: 4.52%
ADAP | $1.085 -4.83% -5.07% 780K

Health Technology

| -34.55% | O: -1.21% H: 5.52% C: 4.91%

Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| -11.42% | O: 0.84% H: 0.0% C: -3.31%
conference

Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
Published: 2022-11-09 (Crawled : 01:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| -1.85% | O: -0.62% H: 4.35% C: 2.48%
financial results

Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
Published: 2022-10-11 (Crawled : 13:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 3.92% | O: -0.65% H: 10.2% C: 3.62%
america disease

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
Published: 2022-08-11 (Crawled : 13:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| -15.87% | O: 2.91% H: 6.94% C: 2.06%
gph101 disease therapy

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
Published: 2022-08-11 (Crawled : 22:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| -15.87% | O: 2.91% H: 6.94% C: 2.06%
results

Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
Published: 2022-05-16 (Crawled : 11:00) - biospace.com/
GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

| 31.4% | O: 7.85% H: 6.51% C: -4.98%
gph102 preclinical pre-clinical

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	27000	27000
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	5371	5371
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	10580	10580
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	54582	54582
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	P	64971	694755
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	P	933038	3319339
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	164729	164729
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	694755	694755
0001415889-24-009077	4	2024-03-26	2024-03-21	Buy	A	2386301	2386301